EGFR and non-small cell lung carcinoma: The success of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the treatment of EGFR mutation–positive advanced NSCLC established a proof of concept that molecularly targeted agents are far more effective than conventional chemotherapy when administered to the appropriate genetically defined patient population (2-7).